Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
VDPHL01 is the potential first and only extended-release oral minoxidil for women and men with pattern hair loss.
read more
The 400,000-square-foot facility will be located at Merck’s site in Elkton, Virginia, where the company has had a presence for almost 85 years.
read more
In a phased investment, ACG will construct and then increase capacity of its facility in Atlanta, Georgia.
read more
Jascayd, an oral treatment for idiopathic pulmonary fibrosis, has received approval in China.
read more
If approved, the drug will be the first oral bone-building therapy for postmenopausal women with osteoporosis.
read more
BridgeBio reported positive topline results from a phase 3 pivotal study of its small molecule oral therapy in individuals living with limb-girdle muscular dystrophy type 2I/R9.
read more
Obesity med giant Novo Nordisk has submitted an unsolicited $9 billion proposal to acquire Metsera, outbidding Pfizer.
read more
After an initial delay, the Bayer's dual neurokinin targeted therapy, Lynkuet, has received FDA approval.
read more
Pfizer has called Novo’s unsolicited buyout bid “an illegal attempt by a company with a dominant market position to suppress competition.”
read more
This past Friday, HHS placed Tidmarsh on administrative leave; two days later, he resigned.
read more
Lilly’s new $3 billion manufacturing plant in the Netherlands will produce oral medications, including its GLP-1 pill.
read more
As a result, the company is currently restructuring to reduce its annual direct R&D spend by 60%.
read more
Metsera announced that it has entered into an amended merger agreement with Pfizer in a deal now worth up to $10 billion.
read more
Fenebrutinib showed positive results for both relapsing and primary progressive multiple sclerosis, making it the first potential BTK inhibitor for MS.
read more
When taken in combination with an oral antidepressant, Caplyta was shown to have superior efficacy and a favorable safety profile.
read more